Trial Profile
A Phase I Study of D-0316 in Patients With Advanced Non Small Cell Lung Cancer With Mutation of Epidermal Growth Factor Receptor Tyrosine Kinase
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Apr 2023
Price :
$35
*
At a glance
- Drugs Befotertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors InventisBio
- 23 Apr 2023 Status changed from active, no longer recruiting to completed.
- 29 Apr 2022 Planned End Date changed from 31 Aug 2021 to 31 Dec 2022.
- 11 Mar 2022 Results published in the Oncologist